Evidence map›Paper›PMID 21680537›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011

Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer.

Adetunji T Toriola, Eva Lundin, Helena Schock, Kjell Grankvist, Eero Pukkala, Tianhui Chen, Anne Zeleniuch-Jacquotte, Paolo Toniolo, Matti Lehtinen, Helja-Marja Surcel and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Adetunji T ToriolaNational Institute for Health and Welfare, Oulu, Finland.
Eva Lundin
Helena Schock
Kjell Grankvist
Eero Pukkala
Tianhui Chen
Anne Zeleniuch-Jacquotte
Paolo Toniolo
Matti Lehtinen
Helja-Marja Surcel
Annekatrin Lukanova
Tampere University · FIInstitute of Social and Preventive Medicine · CHTampere University · FIFinnish Cancer Registry · FIGerman Cancer Research Center · DEUniversity of Lausanne · CH

Funding

Hormone levels during pregnancy and maternal ovarian cancerR01CA120061 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LUKANOVA, ANNEKATRIN · 2006 to 2010
$2.0M
Pregnancy Hormones and Risk of Maternal Breast CancerR01CA114329 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TONIOLO, PAOLO G. · 2005 to 2008
$1.8M
NCI NIH HHS CA114329NCI NIH HHS CA120061NCI NIH HHS R01 CA114329NCI NIH HHS R01 CA120061
6 · The paper itself

Abstract

backgroundElevated serum concentrations of insulin-like growth factor (IGF)-I have been associated with increased risk of developing breast cancer. Previously, we reported a similar association in samples obtained during pregnancy. This study was conducted to further characterize the association of IGF-I during pregnancy with maternal breast cancer risk.

methodsA case-control study was nested within the Finnish Maternity Cohort. The study was limited to primiparous women younger than 40 years, who donated blood samples during early (median, 12 weeks) pregnancy and delivered a single child at term. Seven hundred nineteen women with invasive breast cancer were eligible. Two controls (n = 1,434) were matched with each case on age and date at blood donation. Serum IGF-I concentration was measured using an Immulite 2000 analyzer. Conditional logistic regression was used to estimate ORs and 95% CIs.

resultsNo significant associations were observed between serum IGF-I concentrations and breast cancer risk in both the overall analysis (OR, 1.08; 95% CI, 0.80-1.47) and in analyses stratified by histologic subtype, lag time to cancer diagnosis, age at pregnancy, or age at diagnosis.

conclusionThere was no association between IGF-I and maternal breast cancer risk during early pregnancy in this large nested case-control study. IMPACT: Serum IGF-I concentrations during early pregnancy may not be related to maternal risk of developing breast cancer.

Indexed as

AdultBreast NeoplasmsCase-Control StudiesFemaleHumansInsulin-Like Growth Factor IPregnancyPremenopauseRisk FactorsInsulin-Like Growth Factor I

Identifiers

PMID21680537
PMCPMC3153607
OpenAlexW2096313689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.